Adjuvants designed for veterinary and human vaccines.

Area of Science:

• Vaccinology
• Immunology
• Biotechnology

Background:

• Purified antigens (recombinant proteins, synthetic peptides) offer safety but reduced immunogenicity compared to crude microorganisms.
• Adjuvants are crucial for boosting immune responses to modern, purified vaccine antigens.
• No single adjuvant is universally effective; their mechanisms are complex and varied.

Purpose of the Study:

• To review the role and selection criteria for vaccine adjuvants.
• To discuss different adjuvant formulations, including emulsions and novel 'immunosol' systems.
• To highlight the need for tailored adjuvant strategies balancing safety and immunogenicity.

Main Methods:

• Review of existing literature on vaccine adjuvants and their properties.
• Categorization of adjuvants based on formulation (e.g., water-in-oil, oil-in-water emulsions).
• Discussion of new adjuvant concepts like 'immunosol' combining nanoparticles and immunostimulants.

Main Results:

• Different emulsion types (W/O, O/W, W/O/W) elicit varied immune responses and durations.
• Mineral oil emulsions are potent but may cause local reactions; non-mineral oils are safer but less potent.
• Novel 'immunosol' adjuvants offer a balance of safety and immunogenicity when emulsions are unsuitable.

Conclusions:

• Adjuvant selection must consider species, antigen type, desired immune response, administration route, and duration of immunity.
• Emulsion-based adjuvants provide a range of options, each with specific advantages and disadvantages.
• 'Immunosols' represent a promising new class of adjuvants for optimizing vaccine efficacy and safety.